Provided by Tiger Trade Technology Pte. Ltd.

Renaissance Technologies Holdings

3,002.20
+53.331.81%
Number of Gainers:38
Number of Losers:57
Number of Flat:1
PE:- -
High:3,007.20
Open:2,978.52
Low:2,966.56
Close:2,948.88
Volume:930.35M
Turnover:210.28B
Market Cap:32.74T
Float Cap:30.77T

Loading ...

Lowe's Lowers Full-Year Targets as Homeowners Scale Back DIY Projects

Dow Jones
·
Aug 19

Analysts Offer Insights on Technology Companies: Snowflake (SNOW), Coherent Corp (COHR) and Amplitude (AMPL)

TIPRANKS
·
Aug 19

Moderna Stock Surges 70%, Merck Rises 6%. at Last, a Successful Cancer Vaccine.

Dow Jones
·
Aug 19

AI Spending Just Revealed a $7,000 Gap Between Winners and Losers

InvestorPlace
·
Aug 19

META, MSFT and AMZN Face Rising Costs and Delays as AI Data Center Backlash Grows

TIPRANKS
·
Aug 19

Moderna and Merck Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Moderna jumps 54% to $97.52 after Phase 3 INTerpath-001 trial met endpoints

TIPRANKS
·
Aug 19

Unified Communications Platform Helps Businesses Simplify Communications Across Sparklight Service Areas

GlobeNewswire
·
Aug 19

Moderna Shares Extend Gains; Last up 46.9% Premarket

THOMSON REUTERS
·
Aug 19

Target Q2 Sales Beat; Raises Annual Sales Forecast

Reuters
·
Aug 19

Target Says Value Focus is Paying Off

Dow Jones
·
Aug 19

Google Parent Taps Australian Bond Market for First Time, Raising $3.9 Billion Amid Global Tech Debt Rush

Stock News
·
Aug 19

Target Gains Traction in Grocery

Dow Jones
·
Aug 19

Truist Raises Price Target on CrowdStrike Holdings to $245 From $188, Keeps Buy Rating

MT Newswires Live
·
Aug 19

AI and Robotics are a Battleground for U.S. and China. This is the Best Bet.

Dow Jones
·
Aug 19

Alphabet Raises $3.9 Billion in Inaugural Australian Dollar Bond

Reuters
·
Aug 19

Merck, Moderna Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Target's Promotional Price Cuts Fuel Upgraded FY Revenue Outlook

Dow Jones
·
Aug 19

Merck: Co, Moderna Announce Positive Results from Phase 3 Interpath-001 Trial for Patients with Completely Resected Stage Iib-Iv Melanoma

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Will Engage with Regulators on Filing Submissions for Intismeran Autogene in Combination with Keytruda

THOMSON REUTERS
·
Aug 19